http://www.atsdr.cdc.gov/toxprofiles/tp22.pdf
357 pages. Page 132:
Human and animal studies have investigated the aluminum retention in the body. Within the first day of receiving a single injection of 26Al citrate, approximately 59% of the dose was excreted in the urine of six
subjects; 72 and 1.2% was excreted in the urine and feces, respectively, during the first 5 days (Talbot et al. 1995). At the end of 5 days, it was estimated that 27% of the dose was retained in the body (Priest et
al. 1995; Talbot et al. 1995). When 26 Al levels were monitored more than 3 years after a single subject received the injection, a half-life of approximately 7 years was calculated (Priest et al. 1995). However,
when the subject was re-examined approximately 10 years after the injection, a half-life of about 50 years
was estimated (Priest 2004).
357 pages. Page 132:
Human and animal studies have investigated the aluminum retention in the body. Within the first day of receiving a single injection of 26Al citrate, approximately 59% of the dose was excreted in the urine of six
subjects; 72 and 1.2% was excreted in the urine and feces, respectively, during the first 5 days (Talbot et al. 1995). At the end of 5 days, it was estimated that 27% of the dose was retained in the body (Priest et
al. 1995; Talbot et al. 1995). When 26 Al levels were monitored more than 3 years after a single subject received the injection, a half-life of approximately 7 years was calculated (Priest et al. 1995). However,
when the subject was re-examined approximately 10 years after the injection, a half-life of about 50 years
was estimated (Priest 2004).








